Warning: The NCBI web site requires JavaScript to function. more...
Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study.
Dessein PH, Joffe BI, Stanwix AE.
Arthritis Res. 2002;4(6):R12. Epub 2002 Sep 16.
Related citations
Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis.
Dessein PH, Stanwix AE, Joffe BI.
Arthritis Res. 2002;4(5):R5. Epub 2002 Jun 19.
The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis.
Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z.
J Rheumatol. 2002 Mar;29(3):462-6.
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.
Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ.
Rheumatology (Oxford). 2010 Feb;49(2):295-307. Epub 2009 Nov 27. Review.
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
Aletaha D, Smolen JS.
Rheumatology (Oxford). 2002 Dec;41(12):1367-74.
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
Arthritis Res Ther. 2006;8(5):R151.
Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis.
Dessein PH, Woodiwiss AJ, Joffe BI, Norton GR.
BMC Cardiovasc Disord. 2007 Oct 29;7:31.
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.
J Rheumatol. 2008 Jun;35(6):979-85. Epub 2008 Apr 15.
Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis.
Agarwal V, Mittal SK, Misra R.
Clin Rheumatol. 2009 Apr;28(4):427-33. Epub 2009 Jan 10.
Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.
Kapral T, Stamm T, Machold KP, Montag K, Smolen JS, Aletaha D.
Arthritis Res Ther. 2006;8(2):R46. Epub 2006 Feb 24.
Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM.
Ann Rheum Dis. 2005 Apr;64(4):537-43.
Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
Griffiths RI, Bar-Din M, MacLean CH, Sullivan EM, Herbert RJ, Yelin EH.
Arthritis Care Res. 2000 Aug;13(4):213-26.
Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T, Pincus T.
J Rheumatol. 2002 Dec;29(12):2521-4.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
Clin Ther. 2003 Jun;25(6):1700-21.
Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis.
Stranzl T, Wolf J, Leeb BF, Smolen JS, Pirker R, Filipits M.
Clin Exp Rheumatol. 2003 Jan-Feb;21(1):27-32.
Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, Hetland ML, Hørslev-Petersen K, Hornung N, Poulsen JH, Flyvbjerg A, Stengaard-Pedersen K.
J Rheumatol. 2009 Sep;36(9):1885-91. Epub 2009 Aug 14.
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients.
Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD, Drosos AA.
Semin Arthritis Rheum. 2008 Aug;38(1):13-9. Epub 2008 Jan 14.
How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ.
Rheumatology (Oxford). 2004 May;43(5):619-25. Epub 2004 Feb 24. Erratum in: Rheumatology (Oxford). 2004 Aug;43(8):1065.
Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment.
Bergesio F, Monzani G, Guasparini A, Ciuti R, Gallucci M, Cristofano C, Castrignano E, Cupisti A, Barsotti G, Marcucci R, Abbate R, Bandini S, Gallo M, Tosi PL, Salvadori M.
Clin Nephrol. 2005 Aug;64(2):103-12.
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, Barerra P.
Ann Rheum Dis. 2005 Feb;64(2):303-5. Epub 2004 Jul 1.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on